Clinical Management in Multiple Sclerosis

This review aims to provide a comprehensive overview of the main types, subtypes, clinical manifestations, and current therapeutic strategies for multiple sclerosis, emphasizing recent advancements and clinical challenges. Multiple Sclerosis (MS) is a demyelinating, chronic, autoimmune, and inflamma...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Victoria Arredondo-Robles, Karen Paola Rodríguez-López, Rodolfo Daniel Ávila-Avilés
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Neuroglia
Subjects:
Online Access:https://www.mdpi.com/2571-6980/6/1/6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343116103909376
author Ana Victoria Arredondo-Robles
Karen Paola Rodríguez-López
Rodolfo Daniel Ávila-Avilés
author_facet Ana Victoria Arredondo-Robles
Karen Paola Rodríguez-López
Rodolfo Daniel Ávila-Avilés
author_sort Ana Victoria Arredondo-Robles
collection DOAJ
description This review aims to provide a comprehensive overview of the main types, subtypes, clinical manifestations, and current therapeutic strategies for multiple sclerosis, emphasizing recent advancements and clinical challenges. Multiple Sclerosis (MS) is a demyelinating, chronic, autoimmune, and inflammatory disease that affects the Central Nervous System (CNS). Its classification has the following subtypes: Relapsing-Remitting (RRMS), Secondary-Progressive (SPMS), and Primary-Progressive (PPMS), including rarer subtypes such as Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS), Balo’s Concentric Sclerosis (BCS), Schilder’s Disease (SD), and Progressive-Relapsing MS (PRMS). This article divides the various treatments for MS into the following three categories: acute relapse management, symptomatic treatments, and Disease-Modifying Treatments (DMTs). The latter represents revolutionary research in MS, since they are the drugs considered as the best treatment alternatives for this disease.
format Article
id doaj-art-eaecb97fea404b808a4f3b8b7b1c01bf
institution Kabale University
issn 2571-6980
language English
publishDate 2025-02-01
publisher MDPI AG
record_format Article
series Neuroglia
spelling doaj-art-eaecb97fea404b808a4f3b8b7b1c01bf2025-08-20T03:43:10ZengMDPI AGNeuroglia2571-69802025-02-0161610.3390/neuroglia6010006Clinical Management in Multiple SclerosisAna Victoria Arredondo-Robles0Karen Paola Rodríguez-López1Rodolfo Daniel Ávila-Avilés2Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Mexico City C.P. 07360, MexicoFacultad de Ciencias, Universidad Autónoma del Estado de México, Piedras Blancas, Carretera Toluca Kilómetro 15.5, Ixtlahuaca de Rayón C.P. 50200, Estado de Mexico, MexicoCentro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Mexico City C.P. 07360, MexicoThis review aims to provide a comprehensive overview of the main types, subtypes, clinical manifestations, and current therapeutic strategies for multiple sclerosis, emphasizing recent advancements and clinical challenges. Multiple Sclerosis (MS) is a demyelinating, chronic, autoimmune, and inflammatory disease that affects the Central Nervous System (CNS). Its classification has the following subtypes: Relapsing-Remitting (RRMS), Secondary-Progressive (SPMS), and Primary-Progressive (PPMS), including rarer subtypes such as Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS), Balo’s Concentric Sclerosis (BCS), Schilder’s Disease (SD), and Progressive-Relapsing MS (PRMS). This article divides the various treatments for MS into the following three categories: acute relapse management, symptomatic treatments, and Disease-Modifying Treatments (DMTs). The latter represents revolutionary research in MS, since they are the drugs considered as the best treatment alternatives for this disease.https://www.mdpi.com/2571-6980/6/1/6Multiple Sclerosis (MS)relapsessymptomatic problemsdisease-modifying therapy
spellingShingle Ana Victoria Arredondo-Robles
Karen Paola Rodríguez-López
Rodolfo Daniel Ávila-Avilés
Clinical Management in Multiple Sclerosis
Neuroglia
Multiple Sclerosis (MS)
relapses
symptomatic problems
disease-modifying therapy
title Clinical Management in Multiple Sclerosis
title_full Clinical Management in Multiple Sclerosis
title_fullStr Clinical Management in Multiple Sclerosis
title_full_unstemmed Clinical Management in Multiple Sclerosis
title_short Clinical Management in Multiple Sclerosis
title_sort clinical management in multiple sclerosis
topic Multiple Sclerosis (MS)
relapses
symptomatic problems
disease-modifying therapy
url https://www.mdpi.com/2571-6980/6/1/6
work_keys_str_mv AT anavictoriaarredondorobles clinicalmanagementinmultiplesclerosis
AT karenpaolarodriguezlopez clinicalmanagementinmultiplesclerosis
AT rodolfodanielavilaaviles clinicalmanagementinmultiplesclerosis